Log in

IMAC Stock Forecast, Price & News

-0.03 (-4.05 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $0.71
50-Day Range
MA: $0.99
52-Week Range
Now: $0.71
Volume179,731 shs
Average Volume541,377 shs
Market Capitalization$8.41 million
P/E RatioN/A
Dividend YieldN/A
IMAC Holdings, Inc. operates a chain of integrated medicine and chiropractic regeneration centers. The company's outpatient clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. As of September 17, 2018, it had 11 clinics, including 6 owned and 5 managed clinics in Kentucky, Missouri, and Tennessee, the United States. The company was founded in 2000 and is based in Brentwood, Tennessee.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.82 out of 5 stars

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Current SymbolNASDAQ:IMAC



Sales & Book Value

Annual Sales$15.13 million
Book Value$0.93 per share


Net Income$-6,500,000.00


Market Cap$8.41 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
-0.03 (-4.05 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

IMAC (NASDAQ:IMAC) Frequently Asked Questions

How has IMAC's stock price been impacted by Coronavirus (COVID-19)?

IMAC's stock was trading at $0.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMAC shares have decreased by 13.4% and is now trading at $0.7099.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of IMAC?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMAC in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IMAC

When is IMAC's next earnings date?

IMAC is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for IMAC

How were IMAC's earnings last quarter?

IMAC Holdings Inc (NASDAQ:IMAC) announced its quarterly earnings data on Friday, August, 14th. The company reported ($0.19) earnings per share for the quarter. The business had revenue of $2.57 million for the quarter. IMAC had a negative return on equity of 85.82% and a negative net margin of 46.65%.
View IMAC's earnings history

What price target have analysts set for IMAC?

2 analysts have issued twelve-month price targets for IMAC's shares. Their forecasts range from $4.50 to $4.50. On average, they anticipate IMAC's stock price to reach $4.50 in the next year. This suggests a possible upside of 533.9% from the stock's current price.
View analysts' price targets for IMAC

Are investors shorting IMAC?

IMAC saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 146,400 shares, an increase of 17.0% from the August 15th total of 125,100 shares. Based on an average daily volume of 318,900 shares, the days-to-cover ratio is presently 0.5 days. Currently, 2.0% of the company's shares are sold short.
View IMAC's Short Interest

Who are some of IMAC's key competitors?

What other stocks do shareholders of IMAC own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IMAC investors own include Energy Transfer LP Unit (ET), Biocept (BIOC), Ibio (IBIO), VBI Vaccines (VBIV), Acasti Pharma (ACST), OpGen (OPGN), Amarin (AMRN), Aytu Bioscience (AYTU), Remark (MARK) and McEwen Mining (MUX).

Who are IMAC's key executives?

IMAC's management team includes the following people:
  • Mr. Jeffrey S. Ervin M.B.A., CEO & Director (Age 41)
  • Mr. D. Anthony Bond CPA, Chief Financial Officer (Age 57)
  • Dr. Matthew C. Wallis, COO & Director (Age 45)
  • Mr. Jeff Ervin, Chief Exec. Officer
  • Dr. Ian A. White Ph.D., Chief Scientific Officer (Age 44)

When did IMAC IPO?

(IMAC) raised $4 million in an IPO on the week of February 11th 2019. The company issued 900,000 shares at $5.00 per share. Dawson James Securities and Cuttone acted as the underwriters for the IPO.

What is IMAC's stock symbol?

IMAC trades on the NASDAQ under the ticker symbol "IMAC."

How do I buy shares of IMAC?

Shares of IMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IMAC's stock price today?

One share of IMAC stock can currently be purchased for approximately $0.71.

How big of a company is IMAC?

IMAC has a market capitalization of $8.41 million and generates $15.13 million in revenue each year.

What is IMAC's official website?

The official website for IMAC is www.imacregeneration.com.

How can I contact IMAC?

IMAC's mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The company can be reached via phone at 844-266-4622 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.